|
Market Closed -
OTC Markets
20:01:27 03/06/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.0169 USD | +141.43% |
|
-.--% | +4.00% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.27M 4.45M 3.84M 3.61M 3.28M 6.17M 425M 42.29M 16.54M 213M 16.7M 16.33M 708M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 9.05M 6.41M 5.54M 5.2M 4.73M 8.9M 613M 60.98M 23.84M 307M 24.08M 23.55M 1.02B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +141.43% | ||
| 3 months | -2.03% | ||
| 6 months | +275.56% | ||
| Current year | +4.00% |
| 1 week | 0 | 0.03 | |
| 1 month | 0 | 0.03 | |
| Current year | 0 | 0.03 | |
| 1 year | 0 | 0.05 | |
| 3 years | 0 | 0.06 | |
| 5 years | 0 | 0.1 | |
| 10 years | 0 | 0.28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +141.43% | -.--% | - | - | 4.18M | ||
| -0.10% | -0.77% | +17.58% | +70.16% | 48.43B | ||
| -3.26% | -5.31% | +52.47% | +114.13% | 39.72B | ||
| -0.60% | -0.94% | -7.29% | +17.35% | 12.25B | ||
| -2.75% | +1.88% | +14.81% | +76.92% | 11.84B | ||
| -0.58% | -0.77% | +29.90% | +135.00% | 9.06B | ||
| +1.56% | +5.52% | +23.69% | +41.38% | 7.57B | ||
| +0.52% | +2.08% | +42.23% | -13.42% | 7.18B | ||
| -0.07% | +1.72% | +13.39% | +190.65% | 6.84B | ||
| -2.51% | -3.14% | -30.53% | +23.54% | 5.77B | ||
| Average | +13.36% | +1.46% | +17.36% | +72.86% | 16.52B | |
| Weighted average by Cap. | -1.20% | +1.00% | +24.83% | +80.29% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.61M 3.12M 2.93M 2.66M 5.01M 345M 34.32M 13.42M 173M 13.55M 13.26M 574M | 1.19M 844K 729K 685K 623K 1.17M 80.67M 8.02M 3.14M 40.4M 3.17M 3.1M 134M |
| Net income | -5.8M -4.11M -3.55M -3.34M -3.03M -5.71M -393M -39.1M -15.29M -197M -15.44M -15.1M -654M | -5.94M -4.21M -3.64M -3.42M -3.11M -5.85M -403M -40.08M -15.67M -202M -15.82M -15.48M -671M |
| Net Debt | 759K 538K 465K 437K 397K 747K 51.45M 5.12M 2M 25.77M 2.02M 1.98M 85.62M | 2.77M 1.97M 1.7M 1.59M 1.45M 2.73M 188M 18.69M 7.31M 94.1M 7.38M 7.22M 313M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
- ARUXF Stock
Select your edition
All financial news and data tailored to specific country editions
















